WilmerHale Advises Arteaus Therapeutics in Sale of Emgality Royalty to Royalty Pharma for $260M

WilmerHale Advises Arteaus Therapeutics in Sale of Emgality Royalty to Royalty Pharma for $260M

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

On April 1, 2019, Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company’s (NYSE: LLY) Emgality (galcanezumab), an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million.

WilmerHale represented Arteaus in the deal, with a team led by Steve Singer and Joe Conahan that included Julie Hogan Rodgers, John Sigel, Brandt Tierney and Tyler Rostock.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel